Find Clinical Trial
Effects of agomelatine versus escitalopram on emotional experiences in outpatients suffering from Major Depressive Disorder. An exploratory, randomised, double-blind, international, multicentre study with parallel groups: agomelatine (25 to 50 mg/day) versus escitalopram (10 to 20 mg/day) over a 6- month period. –
← Back
| Study Phase |
Phase 3 |
| Therapeutic Area |
Neuropsychiatric Diseases |
| Indication | Major Depressive Disorder |
| Sponsor | Institut de Recherches Internationales Servier (I.R.I.S) |
| Active substance/ Medical device |
AGOMELATINE, |
| Active Substance Code | S020098 |
| Protocol Code | CL3-20098-060 |
| EudraCT Code | 2011-005320-17 |
Documents and links
| Results summary | READ MORE  |
Quote
| "Goodwin G; Scott E; Reis De Oliveira I; Mcintyre A; Mok YM; Emsley RA; Hall T; Munafo M; Corruble E; Picarel Blanchot F; Marx U; Olivier V; De Bodinat C Eur Neuropsychopharmacol. 2017; 27(Suppl. 4):S788-S789" |
Servier Glossary of Terms
To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.
© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility
